Related Experiment Videos
Radiosynovectomy's clinical applications and cost effectiveness: a review
M E Siegel1, H J Siegel, J V Luck
1Division of Nuclear Medicine, University of Southern California School of Medicine, Los Angeles, USA.
Seminars in Nuclear Medicine
|November 19, 1997
Summary
Radiosynovectomy offers an effective and cost-saving treatment for arthritis and hemophilic joints, providing significant relief and avoiding surgical risks. This procedure is a preferred alternative, especially for hemophilia patients who have not responded to other therapies.
Area of Science:
- Rheumatology
- Nuclear Medicine
- Orthopedics
Background:
- Rheumatoid arthritis and hemophilic joint conditions often involve recurrent joint effusion and hemarthrosis.
- Surgical synovectomy is a traditional treatment but carries risks of postoperative complications like joint stiffness.
Purpose of the Study:
- To evaluate the efficacy and cost-effectiveness of radiosynovectomy as an alternative to surgical synovectomy.
- To assess the favorable response rates and safety profile of radiosynovectomy in treating various forms of arthritis and hemophilic joints.
Main Methods:
- Review of existing literature and clinical data on radiosynovectomy outcomes.
- Analysis of treatment response rates for joint effusion and hemarthrosis.
- Comparison of radiosynovectomy with surgical synovectomy regarding efficacy, side effects, and cost-effectiveness.
Main Results:
- Radiosynovectomy demonstrates a 60-66% favorable response for joint effusion and 75-80% for hemarthrosis in hemophilic joints.
- The procedure avoids postoperative joint stiffness associated with surgery and improves quality of life.
- Significant healthcare cost savings are observed, particularly in the hemophilic population.
Conclusions:
- Radiosynovectomy is an effective and cost-effective alternative to surgical synovectomy for managing arthritis and hemophilic joint issues.
- It is increasingly the preferred treatment for hemophilic patients with recurrent hemarthrosis/synovitis unresponsive to medical therapy or those with clotting factor inhibitors.
- With over 25 years of use and optimized radiopharmaceuticals, the risk of radiation-induced damage is minimal.